Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tae Min Kim

Showing results (191-200 of 588) with videos related to

Pageof 59
Sort By:
International Journal of Clinical Oncology|August 6, 2013
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancerBhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, et al.
Cancer Research and Treatment|February 4, 2021
Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic TreatmentChanghee Park, Miso Kim, Yoonjin Kwak, et al.
Blood|June 21, 2011
Fibrinogen β-derived Bβ(15-42) peptide protects against kidney ischemia/reperfusion injuryAparna Krishnamoorthy, Amrendra Kumar Ajay, Dana Hoffmann, et al.
Cancer Research and Treatment|July 19, 2014
Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsBhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, et al.
The Korean Journal of Internal Medicine|March 29, 2016
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutationsSehhoon Park, Seongyeol Park, Se-Hoon Lee, et al.
Journal of Medical Virology|November 5, 2015
High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphomaYuri Cho, Su Jong Yu, Eun Ju Cho, et al.
Cancer Research and Treatment|October 25, 2013
How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single InstitutionBhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, et al.
Journal of Cancer Research and Clinical Oncology|December 22, 2022
Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell linesJeongjae Lee, Bhumsuk Keam, Ha-Ram Park, et al.
Thoracic Cancer|April 5, 2016
Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitorsSung Hoon Sim, Seung-Hoon Beom, Yong-Oon Ahn, et al.
Diabetes|April 29, 2006
NFATc4 and ATF3 negatively regulate adiponectin gene expression in 3T3-L1 adipocytesHyun Bae Kim, Minyoung Kong, Tae Min Kim, et al.
Pageof 59

Showing results (191-200 of 588) with videos related to

Sort By:
Pageof 59
International Journal of Clinical Oncology|August 6, 2013
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancerBhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, et al.
Cancer Research and Treatment|February 4, 2021
Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic TreatmentChanghee Park, Miso Kim, Yoonjin Kwak, et al.
Blood|June 21, 2011
Fibrinogen β-derived Bβ(15-42) peptide protects against kidney ischemia/reperfusion injuryAparna Krishnamoorthy, Amrendra Kumar Ajay, Dana Hoffmann, et al.
Cancer Research and Treatment|July 19, 2014
Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsBhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, et al.
The Korean Journal of Internal Medicine|March 29, 2016
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutationsSehhoon Park, Seongyeol Park, Se-Hoon Lee, et al.
Journal of Medical Virology|November 5, 2015
High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphomaYuri Cho, Su Jong Yu, Eun Ju Cho, et al.
Cancer Research and Treatment|October 25, 2013
How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single InstitutionBhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, et al.
Journal of Cancer Research and Clinical Oncology|December 22, 2022
Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell linesJeongjae Lee, Bhumsuk Keam, Ha-Ram Park, et al.
Thoracic Cancer|April 5, 2016
Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitorsSung Hoon Sim, Seung-Hoon Beom, Yong-Oon Ahn, et al.
Diabetes|April 29, 2006
NFATc4 and ATF3 negatively regulate adiponectin gene expression in 3T3-L1 adipocytesHyun Bae Kim, Minyoung Kong, Tae Min Kim, et al.
Pageof 59